|  |
| --- |
| **Supplementary** **Table 2.** Summary of all-causality TEAEs through week 80 (treatment + follow-up period) |
| **N (%) of patients** | **Tanezumab****5 mg** **(n = 92)** | **Tanezumab****10 mg** **(n = 93)** | **Celecoxib****200 mg****(n = 92)** |
|  Any TEAE | 70 (76.1) | 63 (67.7) | 67 (72.8) |
|  Serious TEAE | 8 (8.7) | 11 (11.8) | 4 (4.3) |
|  Severe TEAE | 3 (3.3) | 2 (2.2) | 2 (2.2) |
| Treatment discontinuation due to TEAE | 3 (3.3) | 5 (5.4) | 4 (4.3) |
| Study discontinuation due to TEAE | 1 (1.1) | 1 (1.1) | 0 |
| Most common TEAEs\* Nasopharyngitis Back pain Fall Contusion Arthralgia Intervertebral disc protrusion Headache Hypoesthesia Pain in extremity Myalgia Pyrexia Diarrhea Gastroenteritis Musculoskeletal pain Pneumonia Hypertension Constipation Influenza Ligament sprain Arthritis Periarthritis Dizziness Rash | 19 (20.7)7 (7.6)7 (7.6)5 (5.4)11 (12.0)2 (2.2)3 (3.3)6 (6.5)5 (5.4)3 (3.3)2 (2.2)2 (2.2)2 (2.2)3 (3.3)3 (3.3)2 (2.2)1 (1.1)1 (1.1)3 (3.3)06 (6.5)2 (2.2)3 (3.3) | 19 (20.4)7 (7.5)6 (6.5)5 (5.4)5 (5.4)3 (3.2)4 (4.3)3 (3.2)2 (2.2)1 (1.1)2 (2.2)1 (1.1)1 (1.1)1 (1.1)003 (3.2)3 (3.2)3 (3.2)3 (3.2)1 (1.1)1 (1.1)0 | 11 (12.0)9 (9.8)5 (5.4)3 (3.3)7 (7.6)3 (3.3)4 (4.3)5 (5.4)4 (4.3)1 (1.1)5 (5.4)3 (3.3)3 (3.3)4 (4.3)1 (1.1)4 (4.3)1 (1.1)2 (2.2)4 (4.3)1 (1.1)04 (4.3)3 (3.3) |
| \*Reported in ≥ 3% of patients in any treatment group. TEAE = treatment-emergent adverse event. |